Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test

T. Kanematsu, Y. Maehara, T. Matsumata, K. Shirabe, K. Akazawa, K. Sugimachi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Chemosensitivity of hepatocellular carcinoma tissues from 72 patients in 6 antitumor agents was assayed using the succinate dehydrogenase inhibition test. Sensitivity was positive in 47.2% of tissues exposed to adriamycin, 53.5% to mitomycin C, 10.3% to 5-fluorouracil, 51.5% to cisplatin and aclacinomycin A, respectively, and 52.9% to carboquone. Eight percent of the tissues were sensitive to all 6 drugs, while the resistance rate to all drugs was 36.5%. The remaining 55.5% were sensitive to only some of the drugs. When a comparison of the sensitivity to the 6 drugs was made between two different areas of tumors in 16 patients, positive or negative sensitivity was in a range of 76.9-92.9%. The hypovascular masses seen on the angiography and the histologically well differentiated tumors were resistant to adriamycin, a drug most commonly prescribed to treat patients with liver cancer. For some of these tumors, mitomycin C or carboquone may be effective. Our observation shows that the succinate dehydrogenase inhibition test is useful for determining which drugs will be effective for a particular tumor.

Original languageEnglish
Pages (from-to)34-38
Number of pages5
JournalOncology
Volume48
Issue number1
DOIs
Publication statusPublished - Jan 1 1991

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test'. Together they form a unique fingerprint.

  • Cite this

    Kanematsu, T., Maehara, Y., Matsumata, T., Shirabe, K., Akazawa, K., & Sugimachi, K. (1991). Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test. Oncology, 48(1), 34-38. https://doi.org/10.1159/000226891